Filing Details
- Accession Number:
- 0001209191-20-008867
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-12 17:13:07
- Reporting Period:
- 2020-02-10
- Accepted Time:
- 2020-02-12 17:13:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-10 | 8,942 | $240.95 | 58,621 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2020-02-11 | 930 | $243.76 | 57,691 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 2,860 | $244.99 | 54,831 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 3,377 | $245.93 | 51,454 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 1,770 | $246.76 | 49,684 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 1,863 | $247.91 | 47,821 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-11 | 486 | $248.62 | 47,335 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.29 to $244.28).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $244.99 (range $244.37 to $245.36).
- Open market sales reported on this line occurred at a weighted average price of $245.93 (range $245.37 to $246.28).
- Open market sales reported on this line occurred at a weighted average price of $246.76 (range $246.43 to $247.29).
- Open market sales reported on this line occurred at a weighted average price of $247.91 (range $247.44 to $248.43).
- Open market sales reported on this line occurred at a weighted average price of $248.62 (range $248.47 to $248.90).
Billionaire Hedge Funds
